Literature DB >> 27019141

Surface wipe sampling for antineoplastic (chemotherapy) and other hazardous drug residue in healthcare settings: Methodology and recommendations.

Thomas H Connor1, Matthew D Zock2, Amy H Snow3.   

Abstract

Surface wipe sampling for various hazardous agents has been employed in many occupational settings over the years for various reasons such as evaluation of potential dermal exposure and health risk, source determination, quality or cleanliness, compliance, and others. Wipe sampling for surface residue of antineoplastic and other hazardous drugs in healthcare settings is currently the method of choice to determine surface contamination of the workplace with these drugs. The purpose of this article is to review published studies of wipe sampling for antineoplastic and other hazardous drugs, to summarize the methods in use by various organizations and researchers, and to provide some basic guidance for conducting surface wipe sampling for these drugs in healthcare settings.  Recommendations on wipe sampling methodology from several government agencies and organizations were reviewed. Published reports on wipe sampling for hazardous drugs in numerous studies were also examined. The critical elements of a wipe sampling program and related limitations were reviewed and summarized.  Recommendations and guidance are presented concerning the purposes of wipe sampling for antineoplastic and other hazardous drugs in the healthcare setting, technical factors and variables, sampling strategy, materials required, and limitations. The reporting and interpretation of wipe sample results is also discussed.  It is recommended that all healthcare settings where antineoplastic and other hazardous drugs are handled consider wipe sampling as part of a comprehensive hazardous drug "safe handling" program. Although no standards exist for acceptable or allowable surface concentrations for these drugs in the healthcare setting, wipe sampling may be used as a method to characterize potential occupational dermal exposure risk and to evaluate the effectiveness of implemented controls and the overall safety program. A comprehensive safe-handling program for antineoplastic drugs may utilize wipe sampling as a screening tool to evaluate environmental contamination and strive to reduce contamination levels as much as possible, using the industrial hygiene hierarchy of controls.

Entities:  

Keywords:  Antineoplastic drugs; exposure assessment; hazardous drugs; surface wipe sampling healthcare settings

Mesh:

Substances:

Year:  2016        PMID: 27019141      PMCID: PMC5138855          DOI: 10.1080/15459624.2016.1165912

Source DB:  PubMed          Journal:  J Occup Environ Hyg        ISSN: 1545-9624            Impact factor:   2.155


  33 in total

1.  Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States.

Authors:  T H Connor; R W Anderson; P J Sessink; L Broadfield; L A Power
Journal:  Am J Health Syst Pharm       Date:  1999-07-15       Impact factor: 2.637

Review 2.  Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods.

Authors:  Roberta Turci; Cristina Sottani; Giuseppe Spagnoli; Claudio Minoia
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-06-15       Impact factor: 3.205

3.  An analysis to study trends in occupational exposure to antineoplastic drugs among health care workers.

Authors:  Cristina Sottani; Benedetta Porro; Mario Comelli; Marcello Imbriani; Claudio Minoia
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-04-28       Impact factor: 3.205

4.  Assessment of primary, oxidative and excision repaired DNA damage in hospital personnel handling antineoplastic drugs.

Authors:  Milena Villarini; Luca Dominici; Renza Piccinini; Cristina Fatigoni; Maura Ambrogi; Gianluca Curti; Piero Morucci; Giacomo Muzi; Silvano Monarca; Massimo Moretti
Journal:  Mutagenesis       Date:  2010-11-26       Impact factor: 3.000

5.  Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environment.

Authors:  Jack R Pretty; Thomas H Connor; Ivan Spasojevic; Kristine S Kurtz; Jeffrey L McLaurin; Clayton B'Hymer; D Gayle Debord
Journal:  J Oncol Pharm Pract       Date:  2010-12-23       Impact factor: 1.809

Review 6.  Hand dermatitis: a review of clinical features, diagnosis, and management.

Authors:  Deborah A Kedrowski; Erin M Warshaw
Journal:  Dermatol Nurs       Date:  2008-02

7.  Postulating a dermal pathway for exposure to anti-neoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys.

Authors:  H Kromhout; F Hoek; R Uitterhoeve; R Huijbers; R F Overmars; R Anzion; R Vermeulen
Journal:  Ann Occup Hyg       Date:  2000-10

8.  Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan.

Authors:  Jin Yoshida; Shigeki Koda; Shozo Nishida; Toshiaki Yoshida; Keiko Miyajima; Shinji Kumagai
Journal:  J Oncol Pharm Pract       Date:  2010-08-10       Impact factor: 1.809

9.  Exposure of hospital pharmacists and nurses to antineoplastic agents.

Authors:  J J McDevitt; P S Lees; M A McDiarmid
Journal:  J Occup Med       Date:  1993-01

10.  Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system.

Authors:  Chun-Yip Hon; Kay Teschke; Paul A Demers; Scott Venners
Journal:  Ann Occup Hyg       Date:  2014-03-18
View more
  9 in total

1.  Field evaluation of onsite near real-time monitors for surface contamination by 5-fluorouracil.

Authors:  Jerome P Smith; Deborah Sammons; Shirley Robertson; Edward Krieg; John Snawder
Journal:  J Oncol Pharm Pract       Date:  2018-06-27       Impact factor: 1.809

Review 2.  Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs.

Authors:  Christine Roussel; Kristine L Witt; Peter B Shaw; Thomas H Connor
Journal:  Mutat Res Rev Mutat Res       Date:  2017-08-24       Impact factor: 5.657

3.  New approaches to wipe sampling methods for antineoplastic and other hazardous drugs in healthcare settings.

Authors:  Thomas H Connor; Jerome P Smith
Journal:  Pharm Technol Hosp Pharm       Date:  2016-07-27

4.  Environmental assessment of cytotoxic drugs in healthcare settings: protocol for a systematic review and meta-analysis.

Authors:  Laila Al Alawi; Elpidoforos S Soteriades; Marilia Silva Paulo; Linda Östlundh; Michal Grivna; Fatima Al Maskari; Rami H Al-Rifai
Journal:  Syst Rev       Date:  2020-10-19

5.  Development and Proof of Concept of an Audit Toolkit for the Safe Handling of Cytotoxic Drugs in Low- and Middle-Income Countries.

Authors:  Sandrine von Grünigen; Ludivine Falaschi; Nicolas Guichard; Sandrine Fleury-Souverain; Antoine Geissbühler; Pascal Bonnabry
Journal:  JCO Glob Oncol       Date:  2021-09

6.  Evaluation of Closed System Transfer Devices in Preventing Chemotherapy Agents Contamination During Compounding Process-A Single and Comparative Study in China.

Authors:  YiWen Tang; XiaoTian Che; Yao Lei Wang; Xin Ye; Wan Li Cao; Yi Wang
Journal:  Front Public Health       Date:  2022-04-18

Review 7.  Cytostatics in Indoor Environment: An Update of Analytical Methods.

Authors:  M Francisca Portilha-Cunha; A Alves; Mónica S F Santos
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-15

8.  Environmental Contamination and Occupational Exposure of Algerian Hospital Workers.

Authors:  Eline Verscheure; Matteo Creta; Jeroen Vanoirbeek; Meziane Zakia; Taleb Abdesselam; Robin Lebegge; Katrien Poels; Radu-Corneliu Duca; Lode Godderis
Journal:  Front Public Health       Date:  2020-08-05

9.  Consensus Recommendations for the Safe Handling of Cytotoxic Agents in Cytotoxic Academic Research Laboratories (CARL).

Authors:  Shereen Nabhani Gebara; Stephen Barton; Ian Appleford; Pauline McCalla; Graham Sewell; Racha Sabbagh Dit Hawasli
Journal:  J Oncol Pharm Pract       Date:  2020-10-14       Impact factor: 1.809

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.